Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Highlights on endothelins: a review

A Ortega Mateo1, A A de Artiñano

  • 1Departamento de Farmacología, Facultad de Medicina, Universidad Complutense, Madrid, España.

Pharmacological Research
|January 27, 1998
PubMed
Summary

Endothelin-1 is a peptide that can both dilate and constrict blood vessels depending on the context. In healthy conditions, it acts as a vasodilator by activating ETB1 receptors and releasing relaxing factors like nitric oxide. However, in diseases like hypertension and heart failure, it shifts to a vasoconstrictor by binding to ETA and ETB2 receptors. This dual behavior is receptor-specific and influenced by the environment. The review suggests that drugs targeting these receptors could be useful in treating cardiovascular conditions. The synthesis of ET-1 involves endothelin converting enzymes, and its secretion is primarily basolateral in endothelial cells. These findings highlight the importance of understanding receptor activation patterns for developing effective therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nitric oxide reactivity and mechanisms involved in its biological effects.

Pharmacological research·2000
Same author

[Nitric oxide donor molecules].

Medicina clinica·1999
Same author

Endothelial dysfunction and hypertensive vasoconstriction.

Pharmacological research·1999
See all related articles

Area of Science:

  • Cardiovascular pharmacology
  • Endothelial cell signaling
  • Peptide hormone regulation

Background:

The physiological and pathological roles of endothelins remain incompletely understood. While their vasoconstrictive effects are well-documented, their dual actions as vasodilators under normal conditions create uncertainty. Prior research has shown that endothelins influence vascular tone through receptor interactions, but the mechanisms underlying their dual behavior are not fully resolved. This gap motivated investigations into how endothelin-1 interacts with different receptors in various contexts. No prior work had resolved the transition from vasodilation to vasoconstriction in disease states. Understanding these dynamics is essential for developing targeted therapies. The role of endothelin converting enzymes in ET-1 synthesis remains a key focus. Researchers continue to explore how endothelin signaling shifts in pathological conditions.

Purpose Of The Study:

This review aims to clarify the dual physiological and pathological roles of endothelin-1. The specific problem is understanding how ET-1 can act as both a vasodilator and vasoconstrictor depending on context. The motivation stems from the need to identify therapeutic targets for conditions like hypertension and heart failure. The authors propose that receptor-specific activation explains this duality. They suggest that ETB1 receptors mediate vasodilation while ETA and ETB2 receptors mediate vasoconstriction. This distinction is critical for drug development. The review also highlights the importance of endothelin converting enzymes in ET-1 production. These insights could guide future therapeutic strategies.

Keywords:
Endothelin signalingVascular smooth muscleCardiovascular peptidesReceptor activation

Frequently Asked Questions

Endothelin-1 binds to ETA and ETB2 receptors on vascular smooth muscle, increasing intracellular calcium and causing vasoconstriction.

ET-1 activates ETB1 receptors on endothelial cells, releasing nitric oxide and prostacyclin, which relax vascular smooth muscle.

Endothelin converting enzyme is specific to endothelial cells and is necessary for converting precursor proteins into active ET-1.

ETB1 receptors on endothelial cells mediate the release of vasodilatory factors like nitric oxide and prostacyclin.

Related Experiment Videos

Main Methods:

The authors conducted a literature review focusing on endothelin-1's physiological and pathological roles. They analyzed receptor activation patterns in different tissues. The review approach included examining experimental and clinical evidence. They compared ET-1's actions in healthy and diseased states. The synthesis of endothelin peptides from precursor proteins was a key focus. Receptor subtypes ETA, ETB1, and ETB2 were evaluated for their distinct functions. The review also considered the role of endothelin converting enzymes in ET-1 secretion. The authors synthesized findings from multiple studies to propose a comprehensive model.

Main Results:

ET-1 acts as a vasodilator through ETB1 receptors in physiological conditions. It stimulates nitric oxide and prostacyclin release from endothelial cells. In pathological states, ET-1 binds to ETA and ETB2 receptors, causing vasoconstriction. This shift is observed in hypertension and heart failure. The dual action of ET-1 is receptor-specific and context-dependent. Endothelin converting enzymes are critical for ET-1 synthesis. The basolateral secretion of ET-1 from endothelial cells is well-established. These findings suggest that receptor activation patterns determine ET-1's effects.

Conclusions:

The authors propose that ET-1's effects depend on receptor activation patterns. They suggest that ETB1 receptors mediate vasodilation while ETA and ETB2 mediate vasoconstriction. The synthesis and secretion of ET-1 involve endothelin converting enzymes. The dual physiological and pathological roles of ET-1 are receptor-specific. The authors propose that drugs targeting these receptors could be beneficial in disease states. They suggest that ET-1's vasoconstrictive effects are prominent in hypertension and heart failure. The review supports the development of ET antagonists for cardiovascular therapy. These findings could guide future research on endothelin-based treatments.

In pathological conditions, ET-1 preferentially activates ETA and ETB2 receptors, leading to vasoconstriction.

The authors propose that drugs blocking ET-1 production or receptor activation could be beneficial in cardiovascular diseases.